Adverum Biotechnologies (ADVM) Peer Comparison

$4.36

$0.00 (0.00%)

As on 09-Dec-2025 09:30EDT

Market cap

$96 Mln

Revenue (TTM)

$-4 Mln

P/E Ratio

--

P/B Ratio

0.9

Div. Yield

0 %

Edit

	Adverum Biotechnologies (ADVM)	Akero Therapeutics (AKRO)	Leap Therapeutics (LPTX)
Market cap ($ Mln)	96	4,499	116
Revenue ($ Mln)	-4	--	0
Net Profit ($ Mln)	-204.39	-292.82	-98.22
Net Margin (%)	5,677.56	-7,320,500.00	-22,170.65
RoE (%)	--	-28.69	-834.64
Price to Earnings	--	--	--
Price-To-Book	0.93	4.70	27.25

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Adverum Biotechnologies (ADVM)	Akero Therapeutics (AKRO)	Leap Therapeutics (LPTX)
Operating Revenue	-3.60	0.00	0.44
Cost of Revenue	1.68	0.00	31.01
Gross Profit	1.00	-0.02	-0.01
Operating Expenses	206.85	330.02	75.07
Operating Profit (EBIT)	-207.32	-330.02	-105.64
Other Income	0.00	0.00	0.00
Profit before Tax	-204.39	-292.82	-100.25
Provision for Tax	-0.09	0.00	-2.30
Profit after Tax (Net Income)	-204.39	-292.82	-98.22
Minority Interest	0.00	0.00	0.00
Consolidated Profit	0.00	0.00	0.00

Liabilities ($ Mln)

	Adverum Biotechnologies (ADVM)	Akero Therapeutics (AKRO)	Leap Therapeutics (LPTX)
Shareholder's Funds	-55.65	957.64	2.70
Minority Interest	0.00	0.00	0.00
Non-Current Liabilities	83.31	0.29	0.00
Current Liabilities	44.75	47.65	8.70
Total Liabilities	179.84	825.89	49.12

Assets ($ Mln)

	Adverum Biotechnologies (ADVM)	Akero Therapeutics (AKRO)	Leap Therapeutics (LPTX)
Non-Current Assets	43.49	251.04	0.90
Current Assets	28.91	754.54	10.50
Total Assets	179.84	825.89	49.12
Total Debt*	88.94	1.16	0.04
Net Current Assets	-15.84	706.88	0.00

Cashflow ($ Mln)

	Adverum Biotechnologies (ADVM)	Akero Therapeutics (AKRO)	Leap Therapeutics (LPTX)
Cash From Operating Activities	-92.46	-230.11	-60.30
Cash Flow from Investing Activities	-41.89	-109.71	--
Cash from Financing Activities	120.00	445.85	37.18
Net Cash Inflow / Outflow	--	--	--

Ratios

Profitability Ratios

	Adverum Biotechnologies (ADVM)	Akero Therapeutics (AKRO)	Leap Therapeutics (LPTX)
ROCE (%)	-86.23	-37.39	-141.16
ROE (%)	-189.84	-28.69	-834.64
ROA (%)	-107.81	-30.60	-190.64
EBIT Margin (%)	4,048.00	-7,205,162.50	-10,576.52
Net Margin (%)	5,677.56	-7,320,500.00	-22,170.65
Cash Profit Margin (%)	0.00	-488.03	--

Growth Ratios

	Adverum Biotechnologies (ADVM)	Akero Therapeutics (AKRO)	Leap Therapeutics (LPTX)
Revenue Growth (%)	-38.46	-98.59	31.45
EBIT Growth (%)	-24.04	-23.77	26.65
Net Profit Growth (%)	-88.39	-23.44	-27.89
EPS Growth (%)	-97.54	-0.06	0.23
Book Value Growth (%)	-134.32	9.83	-94.53

Valuation Ratios

	Adverum Biotechnologies (ADVM)	Akero Therapeutics (AKRO)	Leap Therapeutics (LPTX)
Price / Earnings	-0.74	-7.79	-1.76
Price / Book Value	1.38	2.62	3.38
Dividend Yield (%)	--	--	--
EV/EBITDA	-0.47	-5.08	-1.02
Market Cap ($ Cr)	--	--	--

Solvency Ratios

	Adverum Biotechnologies (ADVM)	Akero Therapeutics (AKRO)	Leap Therapeutics (LPTX)
Debt to Equity	0.00	0.00	0.00
Short term debt to equity ratio	-0.10	0.00	0.01
Current Ratio	0.65	15.83	1.21
Quick Ratio	0.65	15.83	1.21
Interest Coverage	--	-62.41	-4,357.87

Operating Efficiency Ratios

	Adverum Biotechnologies (ADVM)	Akero Therapeutics (AKRO)	Leap Therapeutics (LPTX)
Debtors to sales (%)	0.00	0.00	0.00
Asset Turnover	-0.02	0.00	0.01
Receivable days	--	--	--
Inventory Days	--	--	--
Payable days	176.53	162,992.81	409,372.20
Cash Conversion Cycle	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly